左心室辅助装置撤除后二尖瓣反流轨迹:VAD WEAN注册报告
基于多中心VAD Wean注册中367例撤除LVAD时二尖瓣反流(MR)<2级且有超声随访的患者,平均随访33.3个月,20.2%进展为≥2级MR,1、3、5、7年累积发生率分别为13.2%、19.6%、26.0%、36.0%。撤除时年龄较大、原植入时MR分级较高、完全移除装置是独立预测因素,男性为保护因素;撤除指征非独立预测因素,≥2级MR与更高死亡、心衰再入院和更低无事件生存相关。
要点
- LVAD撤除时MR<2级者,7年累积≥2级MR发生率达36.0%。
- 撤除时年龄每增1岁,MR进展风险HR 1.04(95%CI 1.02-1.06)。
- 完全移除装置者MR进展风险HR 1.69(95%CI 1.00-2.86)。
核心结论
- LVAD撤除后≥2级MR与进行性心脏重构和不良临床结局相关。
- 撤除时年龄较大、原植入时MR分级较高、完全移除装置是MR进展独立预测因素,男性为保护因素。
- 撤除指征(应答者 vs. 部分应答者)不是MR进展的独立预测因素。
研究设计与样本
- 多中心VAD Wean注册回顾性分析,纳入603例因心脏改善或LVAD相关并发症撤除LVAD的患者。
- 分析纳入367例撤除时MR<2级且此后至少有一次超声心动图随访的患者。
- 主要终点为撤除后1、3、6、12个月及此后每年至10年首次记录到MR≥2级。
- 采用Kaplan-Meier法估计累积发生率,Cox比例风险回归识别独立预测因素。
主要发现
- 平均随访33.3个月,367例中75例(20.2%)出现MR≥2级。
- MR≥2级累积发生率:1年13.2%、3年19.6%、5年26.0%、7年36.0%。
- 独立预测因素:撤除时年龄(HR 1.04/年,95%CI 1.02-1.06,p<0.001)、原植入时MR分级(HR 1.58/级,95%CI 1.17-2.12,p=0.003)、完全移除装置(HR 1.69,95%CI 1.00-2.86,p=0.049);男性为保护因素(HR 0.56,95%CI 0.32-0.98,p=0.042)。
- 发生MR≥2级者死亡率更高(40.5% vs. 19.5%,p=0.013)、心衰再入院更多(68.9% vs. 25.6%,p<0.001)、无事件生存更低(p<0.001)。
临床怎么用
- LVAD撤除后应按照1、3、6、12个月及此后每年至10年的预设时间点行超声心动图监测MR。
- 对撤除时年龄较大、原植入时MR分级较高或完全移除装置的患者,应加强MR随访。
- 发现MR≥2级提示不良结局风险增加,需关注死亡和心衰再入院。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Durable left ventricular assist device (LVAD) support can reduce mitral regurgitation (MR) through ventricular unloading and reverse remodeling. Although improvement in MR during LVAD support is well described, the trajectory of MR after LVAD weaning due to cardiac improvement or LVAD-related complications has not been systematically studied. METHODS: Using the multicenter VAD Wean Registry, we identified 603 patients who underwent LVAD weaning due to either cardiac improvement or LVAD-related complications. The present analysis included 367 patients with less than moderate MR (grade <2) at the time of weaning and at least one echocardiographic follow-up assessment thereafter. The primary endpoint was moderate or greater MR (grade ≥2). MR was assessed at predefined echocardiographic follow-up timepoints: 1, 3, 6, and 12 months after weaning, then annually up to 10 years. The primary endpoint was defined as the first documentation of ≥2 MR at any of these timepoints. Kaplan-Meier analysis was used to estimate cumulative incidence, and Cox proportional hazards regression to identify independent predictors. RESULTS: Over a mean follow-up of 33.3 months, 75 of 367 patients (20.2%) developed ≥2 MR. The cumulative incidence was 13.2% at 1 year, 19.6% at 3 years, 26.0% at 5 years, and 36.0% at 7 years. Independent predictors of developing worsening MR included older age at weaning (HR 1.04 per year, 95% CI 1.02-1.06, p < 0.001), higher MR grade at original implantation (HR 1.58 per grade, 95% CI 1.17-2.12, p = 0.003), male sex as a protective factor (HR 0.56, 95% CI 0.32-0.98, p = 0.042), and complete device explantation (HR 1.69, 95% CI 1.00-2.86, p = 0.049). The indication for weaning (responder vs. partial responder) was not an independent predictor. Development of ≥2 MR was associated with higher mortality (40.5% vs. 19.5%, p = 0.013), more heart failure readmissions (68.9% vs. 25.6%, p < 0.001), and lower event-free survival (p < 0.001). CONCLUSIONS: Moderate or greater MR after LVAD weaning is associated with progressive cardiac remodeling and adverse clinical outcomes. Future research is warranted to investigate whether interventions targeting the modifiable factors we identified being associated with the development of MR can further improve outcomes.
引用
- Bhadra OD, Pausch J, Patel SR, et al. Mitral regurgitation after left ventricular assist device weaning for cardiac recovery or left ventricular assist device-related complications: A VAD WEAN Recovery Networkreport. J Heart Lung Transplant. 2026. PMID: 42753992. doi:10.1016/j.healun.2026.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。